CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Price, Quote, News and Overview
NYSEARCA:CLDI - NYSE Arca - US3207033099 - Common Stock - Currency: USD
CLDI Quote, Performance and Key Statistics
1.05
-0.21 (-16.67%)
The current stock price of CLDI is 1.05 USD. In the past month the price increased by 37.98%. In the past year, price decreased by -89.81%.
CLDI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CLDI
Company Profile
Calidi Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2021-09-10. Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The firm's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
Company Info
CALIDI BIOTHERAPEUTICS INC
4475 Executive Drive, Suite 200
San Diego CALIFORNIA US
Employees: 41
Company Website: https://www.calidibio.com/
Investor Relations: http://calidibio.com/investors/
Phone: 18587949600
CALIDI BIOTHERAPEUTICS INC / CLDI FAQ
What is the stock price of CALIDI BIOTHERAPEUTICS INC today?
The current stock price of CLDI is 1.05 USD. The price decreased by -16.67% in the last trading session.
What is the ticker symbol for CALIDI BIOTHERAPEUTICS INC stock?
The exchange symbol of CALIDI BIOTHERAPEUTICS INC is CLDI and it is listed on the NYSE Arca exchange.
On which exchange is CLDI stock listed?
CLDI stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for CALIDI BIOTHERAPEUTICS INC stock?
8 analysts have analysed CLDI and the average price target is 6.38 USD. This implies a price increase of 507.14% is expected in the next year compared to the current price of 1.05. Check the CALIDI BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CALIDI BIOTHERAPEUTICS INC worth?
CALIDI BIOTHERAPEUTICS INC (CLDI) has a market capitalization of 27.22M USD. This makes CLDI a Nano Cap stock.
How many employees does CALIDI BIOTHERAPEUTICS INC have?
CALIDI BIOTHERAPEUTICS INC (CLDI) currently has 41 employees.
What are the support and resistance levels for CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
CALIDI BIOTHERAPEUTICS INC (CLDI) has a resistance level at 1.29. Check the full technical report for a detailed analysis of CLDI support and resistance levels.
Should I buy CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLDI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLDI, evaluating the profitability, health, valuation and growth aspects
- CALIDI BIOTHERAPEUTICS INC (CLDI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Sales and EPS estimates to see what analysts future expectations are.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Insider and Institutional Ownership to learn about the owners and their transactions.
- CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Chart to make your own analysis
- CALIDI BIOTHERAPEUTICS INC (CLDI) Latest news and press-releases to stay up to date.
Does CALIDI BIOTHERAPEUTICS INC (CLDI) stock pay dividends?
CLDI does not pay a dividend.
When does CALIDI BIOTHERAPEUTICS INC (CLDI) report earnings?
CALIDI BIOTHERAPEUTICS INC (CLDI) will report earnings on 2025-03-14, after the market close.
What is the Price/Earnings (PE) ratio of CALIDI BIOTHERAPEUTICS INC (CLDI)?
CALIDI BIOTHERAPEUTICS INC (CLDI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.6).
What is the Short Interest ratio of CALIDI BIOTHERAPEUTICS INC (CLDI) stock?
The outstanding short interest for CALIDI BIOTHERAPEUTICS INC (CLDI) is 2.7% of its float. Check the ownership tab for more information on the CLDI short interest.
CLDI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLDI. When comparing the yearly performance of all stocks, CLDI is a bad performer in the overall market: 98.56% of all stocks are doing better.
CLDI Financial Highlights
Over the last trailing twelve months CLDI reported a non-GAAP Earnings per Share(EPS) of -9.6. The EPS increased by 2.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -387.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLDI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to CLDI. The Buy consensus is the average rating of analysts ratings from 8 analysts.